What is the recommended dilution for Ceftazidime (Ceftazidime) and Avibactam (Avibactam) intravenous (IV) administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftazidime-Avibactam IV Dilution and Administration

Ceftazidime-avibactam should be administered as 2.5 grams (2000 mg ceftazidime + 500 mg avibactam) infused intravenously over 2 hours every 8 hours for patients with normal renal function (creatinine clearance >50 mL/min). 1, 2, 3

Standard Dilution and Infusion Protocol

The recommended administration method is a 2-hour intravenous infusion every 8 hours, which has been validated through extensive pharmacokinetic/pharmacodynamic modeling and clinical trials. 2, 3

  • The standard adult dose is 2.5 g (2000 mg ceftazidime + 500 mg avibactam) administered every 8 hours via 2-hour IV infusion 1, 2
  • This dosing regimen achieves optimal pharmacodynamic targets with >95% target attainment against MICs ≤8 mg/L regardless of patient factors including obesity, older age, or augmented renal clearance 2

Renal Dose Adjustments

Dosage modifications are required for patients with creatinine clearance ≤50 mL/min, as both ceftazidime and avibactam are renally eliminated. 2

  • Patients with CLCR >50 mL/min: Standard dose of 2.5 g every 8 hours 2
  • Modified dosing regimens exist for CLCR ≤50 mL/min, though specific adjustments should follow manufacturer guidelines 2

Pediatric Dosing Considerations

For pediatric patients, weight-based dosing is recommended with maximum dose limits:

  • Children ≥6 months: 50 mg/kg/dose (ceftazidime component) IV every 8 hours 4
  • Maximum dose: 2000 mg ceftazidime per dose 4
  • Children 3 to <6 months: 40 mg/kg/dose IV every 8 hours 4

Alternative Administration: Continuous Infusion

Continuous infusion (CI) represents an emerging alternative administration strategy, though it is not yet FDA-approved and requires therapeutic drug monitoring. 5

  • CI dosing of 5 g every 12 hours has shown promising results in small case series 5
  • This approach requires therapeutic drug monitoring with target ceftazidime levels of ≥4-5 × MIC in plasma 5
  • CI achieved clinical cure in 80% and microbiological eradication in 90% of cases in one retrospective series 5
  • This approach should only be used with therapeutic drug monitoring capabilities and infectious disease consultation 5

Critical Pharmacodynamic Principles

The efficacy of ceftazidime-avibactam depends on maintaining adequate concentrations of both components simultaneously:

  • Ceftazidime target: 50% free time above the MIC 2
  • Avibactam target: free time above a critical threshold concentration of 1 mg/L 2
  • The 2-hour infusion over 8-hour dosing interval optimally achieves these joint pharmacodynamic targets 2

Common Pitfalls to Avoid

Do not administer as a rapid IV push or short infusion (<2 hours), as this fails to optimize the time-dependent killing characteristics of beta-lactams and may compromise avibactam's ability to maintain adequate inhibitory concentrations throughout the dosing interval. 2

  • Avoid extending the dosing interval beyond 8 hours in patients with normal renal function, as avibactam concentrations may drop below the critical 1 mg/L threshold needed for beta-lactamase inhibition 6
  • Do not use standard ceftazidime dosing without the avibactam component for resistant organisms, as ceftazidime alone has no effect against beta-lactamase-producing pathogens 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.